In this study we performed a meta-analysis on the adverse events related with the treatment with rimonabant, a cannabinoid-1 receptor blocker, used primarily in obesity and related disorders. The gene discussed is CNR1; the disease is obesity due to melanocortin 4 receptor deficiency.